Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt (I2 and thyroid)

September 21, 2021 updated by: Mehwish Iftikhar, Services Institute of Medical Sciences, Pakistan

Frequency of Florid Hyperthyroidism In Patients Taking Iodinated Salt: A Cross Sectional Study

Thyroxin a vital hormone for life lot of body functions depend on proper functioning on pituitary thyroid axis. it exists in two major forms Thyroxine (T4) and (T3) , each of them containing two iodine atoms on their inner (tyrosine) ring. Synthesis of reasonable quantities of thyroid hormones requires adequate iodine intake to allow sufficient thyroidal uptake. The World Health Organization (WHO) recommendation for daily intake of iodine is 150 μg for children ≥12 years and adults, and 250 μg for pregnant and lactating women. However as we know optimum amount of iodine is required for normal pituitary thyroid axis like wise excessive intake may cause over functioning of axis hence over production of hormone that can be manifested both clinically and biochemically.

This study is designed to observe the frequency of over hyperthyroidism in patients taking iodinated salt.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

All patients presenting to endocrine clinic fulfilling inclusion and exclusion criteria will be recruited. They will be examined, their vitals including blood pressure pulse will be noted, thyroid clinical examination including eye signs and thyroid status will be done biochemical Thyroid profile (TSH, Free T3 & Free T4) will be noted in predesigned proforma.

Statistical Analysis will be done ,after data is entered in Statistical Package for the Social Sciences (SPSS) version 25 .qualitative data will be presented as frequencies and percentages while quantitative data will be presented as mean medians and standard deviations.

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan, 54000
        • Mehwish Iftikhar
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients presenting with biochemical hyperthythyroidism and taking Iodinated salt with age range of 18-60 years

Description

Inclusion Criteria:

  1. All patients presenting with biochemical hyperthyroidism
  2. Who are taking Iodinated salt.
  3. Treatment naïve patients
  4. Both genders included
  5. All patients who can give consent (18-60 years)

Exclusion Criteria:

1) Pregnant females 2) Lactating mothers

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Affect of Iodinated Salt on Thyroid Status
Time Frame: through study completion an average of 12 weeks
Affect of Iodinated Salt on Thyroid Status
through study completion an average of 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Services Institute of Medical Sciences, Pakistan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

October 1, 2021

Primary Completion (ANTICIPATED)

March 1, 2022

Study Completion (ANTICIPATED)

March 1, 2022

Study Registration Dates

First Submitted

March 16, 2021

First Submitted That Met QC Criteria

March 19, 2021

First Posted (ACTUAL)

March 22, 2021

Study Record Updates

Last Update Posted (ACTUAL)

September 22, 2021

Last Update Submitted That Met QC Criteria

September 21, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1241985

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Dysfunction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe